Delia A. Deschaine
Delia Deschaine has long represented pharmaceuticals and biotechnology clients in cases involving U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) enforcement and litigation.
She conducts internal investigations, represents clients in civil and criminal investigations, and routinely counsels clients on their compliance obligations under current Good Manufacturing Practices (cGMPs). Delia also works with clients regarding domestic and foreign inspections, including responding to FDA Form 483s and warning letters. Clients turn to Delia for guidance on FDA and DEA regulation of pharmaceuticals, including controlled substances and listed chemicals.
Delia is well versed in the federal and state regulation of controlled substances. She served as a lawyer in the U.S. Attorney General’s Honors Program, Drug Enforcement Administration, and has represented clients in many criminal, civil, and administrative investigations, and litigation brought by and against the DEA. She routinely counsels clients on their compliance obligations under the Controlled Substances Act regarding registration, security, recordkeeping, and reporting, and has represented national organizations in developing their suspicious order monitoring and supply chain integrity programs.
Delia's controlled substances experience is informed by her work as a lawyer advocate for a public interest organization, focusing on remedying the legal and systemic barriers that prevent access to addiction treatment services.
Held leading role in high-profile government investigation and subsequent litigation involving wholesale distribution of controlled substances.*
Represented a national pharmacy chain in civil, criminal, and administrative investigations regarding compliance with the CSA and CMEA.
*Matter handled prior to joining Hogan Lovells.